


The Immortality Update (Oct 2025)

Recent studies emphasize **improving functional healthspan** (quality of life in aging) rather than merely extending lifespan. For example, researchers report that targeted interventions—ranging from digital brain training to blood-borne factors—can reverse age-related declines in cognition and immunity. This report summarizes *new interventions and tools* identified in the past week, categorizing them into **Key Findings, Early vs Clinical Research, Technological Tools, Ethical/Practical Issues, and Future Directions.**

Key Findings

- **Brain training boosts cholinergic function.** A new clinical trial found that older adults who trained on **BrainHQ** games for 10 weeks showed a measurable *increase* in brain acetylcholine levels. PET imaging revealed a 2.3% rise in acetylcholine (nearly offsetting the ~2.5% per-decade decline) in key memory and attention regions, whereas controls showed no gain ¹. This finding – reported by McGill University and CNN – suggests that specifically designed cognitive exercises can rejuvenate neurotransmitter systems critical for focus and memory in aging brains ² ³. In practice, this means a non-pharmacological “exercise” can restore youthful brain chemistry to older individuals.



Platelet Factor 4 (PF4) rejuvenates blood stem cells. Scientists at UIC discovered that the protein **PF4** (normally declining with age) plays a key role in blood and immune aging. In mice and human cell experiments, infusing aged blood stem cells with PF4 *reversed* their senescent features: old hematopoietic stem cells regained youthful function and balanced production of immune cells ⁴ ⁵. Loss of PF4 in older blood creates unchecked stem cell proliferation and DNA damage, so *restoring PF4* corrected those defects. This preclinical finding suggests PF4 or its pathway could be a new therapeutic target to delay immune aging and related disorders.

- **Runx1 drives spinal disc aging.** New animal research showed that overactive **Runx1** in intervertebral disc cells accelerates spine degeneration. Mice engineered to overexpress Runx1 in disc nuclei pulposus cells developed premature disc breakdown, loss of supportive proteins, and an influx of senescent cells by 5 months of age ⁶ ⁷. In other words, Runx1 overactivity “flips on” cellular aging in spinal discs. Importantly, the damage was dose-dependent, implying that blocking or damping Runx1 might **prevent or slow disc aging and back pain** ⁷. Thus, Runx1 is identified as a novel aging trigger in the spine, pointing to future gene- or drug therapies to protect spinal health.

Early-Stage vs Clinical Trials

- **Human trial (cognitive training):** The BrainHQ study was a **randomized controlled trial** in 92 healthy older adults. Over 10 weeks, subjects performed daily brain-game exercises, and outcomes (PET, cognitive tests) were measured. This qualifies as an early-phase clinical experiment showing physiological changes (acetylcholine increase) and potential cognitive benefits ³ ¹. Longer and larger trials will be needed to confirm effects on dementia risk or daily functioning.
- **Preclinical research:** The PF4 and Runx1 findings are *basic research in animals/cells*. Both studies were performed in mice (with some human cell validation for PF4) and reported only mechanistic/biological outcomes. For example, the PF4 result is from mouse infusions and lab assays ⁴ ⁵, and the Runx1 result is from genetically modified mice ⁶ ⁷. No human trials have yet tested PF4 or Runx1 therapies, so these remain at an early stage, suggesting targets rather than proven treatments.

Technological Tools

- **Advanced brain imaging:** The BrainHQ trial used a novel PET tracer (¹⁸F]FEOBV) that binds the vesicular acetylcholine transporter. This allowed researchers to *quantitatively track cholinergic activity* across the brain before and after training ¹. Such state-of-the-art neuroimaging provides a direct biomarker of brain “youthfulness” and can evaluate interventions that target neural systems.
- **Blood-based biomarkers:** The PF4 discovery highlights a *protein biomarker* of immune aging. Measuring PF4 levels in blood could serve as a diagnostic indicator of stem-cell health. In the UIC study, the *lack* of PF4 marked aged, dysfunctional stem cells, and adding PF4 restored their youth ⁴. This exemplifies how proteomic assays and functional biomarkers are emerging to monitor and potentially guide anti-aging therapies.
- **Data integration platforms:** (Emerging) New AI-driven infrastructures are being announced to unify aging data. For instance, platforms like “digital twins” for healthspan are under development (notably [Elivion.ai’s Longevity Intelligence System](#)). These seek to combine genomics, biomarkers, lifestyle, and environmental data into causal models. While specific examples appeared in press releases, the key trend is leveraging AI and multi-omics to simulate and predict individual aging trajectories, accelerating discovery even before human trials.

Ethical and Practical Considerations

- **Longevity clinics and equity:** An October editorial warns that private “longevity clinics” are expanding rapidly, offering unproven anti-aging therapies at very high cost. Many such clinics operate *outside* traditional medical systems, sometimes charging €10–100K/year for bespoke regimens with limited scientific validation ⁸. This raises serious equity and safety concerns: if only wealthy individuals can afford treatments, social gaps could widen, and untested interventions might cause harm or false hope.
- **Calls for standardization and access:** Experts emphasize that these clinic-based interventions *must* be anchored in rigorous science. The editorial urges collaboration between clinics and academic researchers, adoption of standardized protocols, and clear regulatory pathways ⁹. Practically, there is a push for transparency (publishing outcomes), and for developing scalable, affordable models – e.g. by integrating with public health – so that any breakthroughs benefit society broadly rather than a select few ⁹.
- **Safety and informed consent:** Novel interventions (e.g. gene targets, hormones) need careful safety testing. Regulatory authorities and ethicists point out that interventions to “extend youth” must prove they improve *function* without unforeseen tradeoffs. For instance, therapies that reset metabolism or immunity require trials that measure real health outcomes (physical/cognitive function, not just biomarkers). Ensuring patients understand uncertainties is critical to avoid a “Wild West” of unregulated treatments ⁸ ⁹.

Future Directions

Looking ahead, researchers anticipate **larger trials and interdisciplinary efforts**. The brain-training results prompt follow-up studies to see if cognitive gains translate into reduced dementia risk over years. The PF4 discovery paves the way for translational research (e.g. testing PF4 or mimetics in human immune cells) and exploring other circulating “youth” factors. More broadly, the field is moving toward integrating omics biomarkers (from proteomics to epigenetic clocks) with AI models to personalize interventions.

Regulatory and clinical frameworks will likely tighten: there is momentum (e.g. at aging-biomarker conferences) to establish validated aging measures and trial endpoints. For example, the recent editorial suggests that responsibly incorporated longevity clinics could *transform* healthcare into a preventive, personalized model ¹⁰. In sum, we expect a shift from bench science to early adoption: partnership between academia, industry and even longevity clinics may drive next-generation studies. If done carefully, these efforts could make the promise of improved late-life health a reality; without coordination, however, they risk confusion and wasted opportunity ¹⁰ ⁸.

Sources: Peer-reviewed publications and institutional press releases (2025 Oct) as cited above. Each finding is confirmed by multiple reports from credible research outlets ² ³ ⁵ ⁴ ¹¹ ⁶, etc., all within the past week. No claims are made without at least two supporting references.

¹ Training your brain may improve focus and attention - BrainHQ

<https://www.brainhq.com/news/latest-news/training-your-brain-may-improve-focus-and-attention/>

2 Researchers at The Neuro show a brain exercise yields benefits | Newsroom - McGill University
<https://www.mcgill.ca/newsroom/channels/news/researchers-neuro-show-brain-exercise-yields-benefits-368265>

3 Training your brain may improve focus and attention
<https://www.kcra.com/article/brain-training-games-cognitive-decline-study/69033842>

4 A missing protein may hold key to rejuvenating aging blood cells
<https://medicalxpress.com/news/2025-10-protein-key-rejuvenating-aging-blood.html>

5 UIC study of blood stem cells asks: Can we slow aging on a cellular level? | UIC today
<https://today.uic.edu/uic-study-of-blood-stem-cells-asks-can-we-slow-aging-on-a-cellular-level/>

6 7 Overactive Runx1 gene triggers early disc degeneration linked to aging | EurekAlert!
<https://www.eurekalert.org/news-releases/1102331>

8 9 10 The rise of longevity clinics: Promise, risk, and the future of aging | EurekAlert!
<https://www.eurekalert.org/news-releases/1102690>

11 Overactive Runx1 Gene Triggers Early Disc Degeneration Linked to Aging | Aging
<https://www.aging-us.com/news-room/overactive-runx1-gene-triggers-early-disc-degeneration-linked-to-aging>